News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Biovail Corporation Settles Cardizem Case with $22.2 Million Fine
September 15, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- A U.S. unit of Canadian drugmaker Biovail Corp has pleaded guilty to conspiracy and kickback charges, ending a case over its Cardizem hypertension drug, the U.S. Justice Department said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Vaccines
ACIP Meeting Delayed as Turbulence Rocks CDC, US Vaccine Policy
February 20, 2026
·
2 min read
·
Tristan Manalac
Government
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
February 19, 2026
·
3 min read
·
Tristan Manalac
CDC
NIH’s Jay Bhattacharya Steps In as Acting CDC Chief
February 18, 2026
·
1 min read
·
Annalee Armstrong
Legal
Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus
February 18, 2026
·
2 min read
·
Tristan Manalac